StockNews.AI
ATNM
StockNews.AI
144 days

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

1. A class action lawsuit has been filed against Actinium Pharmaceuticals. 2. Allegations include misleading statements about Iomab-B's FDA approval prospects. 3. Stock price declined significantly after revealing Sierra Trial data issues. 4. Investors are advised to contact the firm for representation. 5. Class period covers purchases between October 31, 2022, and August 2, 2024.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit's allegations present significant risks to ATNM, echoing previous instances like Valeant Pharmaceuticals, which faced severe repercussions from similar legal troubles, leading to a notable market decline.

How important is it?

Class action lawsuits often negatively affect investor sentiment and stock prices, particularly in biotech where FDA outcomes are critical.

Why Short Term?

The immediate news cycle surrounding the lawsuit is likely to influence stock prices quickly, as seen with recent class action impacts on biotech firms like Athersys, whose stocks dropped sharply after litigation announcements.

Related Companies

VRTXMDGLAthersys
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the federal securities laws. The Complaint alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges that the Defendants failed to disclose to investors that: (1) the Company’s data from Sierra Trial was unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial’s poor OS data were unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. According to the Complaint, the truth began to reach the market on August 5, 2024, when the Company announced that “the analyses from the Sierra Trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study,” and Actinium’s stock price suffered significant declines, harming investors. Investors who purchased or otherwise acquired shares of Actinium should contact the Firm prior to the May 26, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com. Please visit our website at http://www.gme-law.com for more information about the firm.

Related News